Press Release

According to the global biosimilar market report by IMARC Group, the market reached a value of US$ 3.8 Billion in 2018. the market is projected to expand at a CAGR of nearly 33% during 2019-2024, registering a value of US$ 20.2 Billion by 2024. Biosimilars, also known as subsequent entry biologics (SEBs) or follow-on biologics, refer to FDA-approved biotherapeutic products which are similar to their reference biologics. Biosimilars can only be manufactured after the patent of the reference product expires. The demand for biosimilars has been increasing in recent years as they help in reducing the overall cost of the treatment for a variety of chronic diseases including cancers, autoimmune diseases, kidney failure, diabetes, CVDs, hematological disorders, infectious diseases, rheumatoid arthritis, growth hormone deficiency, etc.

For more information about this report visit: https://www.imarcgroup.com/biosimilar-market

Global Biosimilar Market Trends:

Recent patent expiries of a large number of blockbuster biological drugs such as Humira, Remicade, MabThera, Enbrel, etc. have majorly boosted the growth of the biosimilar market. Another major growth-inducing factor is ageing population which has led to a rise in the prevalence of non-communicable diseases. Further, high costs of innovator biologics, especially monoclonal antibodies (mAbs), have encouraged several governments across the globe to promote the usage of biosimilars. For instance, European countries like the Netherlands, Denmark and Germany have established strategic models for discount pricing and introduced numerous incentive programs.

Apart from this, biosimilars do not require extensive marketing as the safety and efficacy profile of biologics has already been established. This has resulted into the low cost of these drugs in comparison to their branded counterparts, in turn, spurring their demand worldwide.

Get a PDF Sample for more detailed market insights: https://www.imarcgroup.com/biosimilar-market/requestsample

Global Biosimilar Market Segmentation:

Market Breakup by Molecule

1. Infliximab
2. Insulin Glargine
3. Epoetin Alfa
4. Etanercept
5. Filgrastim
6. Somatropin
7. Rituximab
8. Follitropin Alfa

Market Breakup by Type of Manufacturing

1. In-house Manufacturing
2. Contract Manufacturing

Market Breakup by Indication

1. Auto-Immune Diseases
2. Blood Disorder
3. Diabetes
4. Oncology
5. Growth Deficiency
6. Female Infertility

Market Breakup by Region

1. Europe
2. United States
3. Japan
4. India
5. South Korea
6. Rest of the World

Some of the key players operative in the market are Sandoz International GmbH, Pfizer Inc., Teva Pharmaceutical Industries Limited, Celltrion Inc., Biocon Limited, Samsung Biologics, Amgen, Inc., Dr. Reddy’s Laboratories Limited and Stada Arzneimittel Ag.

Do You Have Any Query or Specific Requirement? Ask to Our Industry Expert https://www.imarcgroup.com/request?type=report&id=497&flag=C

Contact US: IMARC Group
309 2nd St, Brooklyn, NY 11215, USA
Website: www.imarcgroup.com
Email: [email protected]
USA: +1-631-791-1145
Follow us on twitter: @imarcglobal
Linkedin: https://www.linkedin.com/company/imarc-group

This post was originally published on Stock Markets News

imarcgroup
imarcgroup
https://www.imarcgroup.com/
[email protected]

IMARC Group is a leading market research company that provides market and business research intelligence across the globe. We partner with clients in all regions and industry verticals to identify their highest-value opportunities, address their most critical challenges, and transform their businesses. We make an effort to fulfill specific and niche requirements of the industry while balancing the quantum of quality with stipulated time and trace major trends at both the domestic and global levels. The information products and services provided by IMARC cover major technological, scientific and economic developments in industrial, pharmaceutical and high technology organizations.